|
FORMULATION & PROCESS DEVELOPMENT FOR ORAL DOSAGE FORMS
"A 5-Day Modular and Case Study Oriented Training Program"
Historical Location & Reputable Speakers
April 19- 23, 2010, Nassau Inn, New
Jersey, USA |
|
(SOME OF THE)
PHARMACEUTICAL COMPANIES REPRESENTED BY ATTENDEES AT THE PAST
EVENTS:
Array BioPharma; Astellas Pharma. Inc. (JAPAN);
AstraZeneca,; Barr Pharmaceuticals; Bayer HealthCare;, Bayer
Schering Pharma (GERMANY); Bristol-Myers Squibb Co.; CJ Corp
(KOREA); Cubist Pharmaceuticals, Inc.; Eli Lilly and
Company; Frontage laboratories, Inc.; Gador S.A (ARGENTINA);
Genzyme (IRELAND); Gilead Sciences Inc.; Impax
Laboratories; Intermune; ISP Pharma Systems; Kyowa Pharmaceutical,
Inc.; Lannett Company Inc.; MedImmune, Inc.; Merck & Co., Inc.;
Neurogen Corporation; Novartis ; Orion Corporation ORION PHARMA (FINLAND);
Perrigo Company; Pfizer Pharmaceuticals, LLC; PGM-Pfizer Caguas
(PUERTO RICO); Procter & Gamble Pharmaceuticals; Schering Plough
Corporation; Schering Plough Research Institute; Supernus
Pharmaceuticals, Inc.; Teva Pharmaceuticals ; Teva Pharmaceuticals
Ltd. (ISRAEL); Tunnell Consulting; Tyco
Healthcare/Mallinckrodt; Upsher-Smith Laboratories, Inc.; URL/Mutual
Pharmaceutical Company; VPS Corporation; Watson Laboratories Inc |
|
Innovative Modular Format
Crystal Form of
APIs
Preformulation
Formulation & Process Development Guidelines
Milling, Mixing,
and Flow
Granulation
Tableting/Compaction
Film
Coating
Technology
Transfer
Stability
|
 |
Critical/Current Issues
Solubility
Polymorphism
Stability
Formulation Development Strategies
Selection of excipients
Excipient Functionality
Considerations
Process Development
Strategies
Scale-Up
Trouble Shooting
Validation
SUPAC
Design Space and other
PAT Related Issues |
